Pressemitteilung BoxID: 379203 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Marc Heydrich
  • +49 (30) 75019-134

aap Achieves Total Nine-Month Sales of EUR 20.9 Million

Adjusted 14.3 Percent Sales Growth at Product Level / Additional Project Revenue due to Divestment

(PresseBox) (Berlin, ) aap Implantate AG, a medical technology company listed in the Prime Standard segment of the Frankfurt Stock Exchange, achieved according to preliminary figures total sales of EUR 20.9 million (previous year: EUR 25.6 million) in the first nine months of the fiscal year 2010, including EUR 0.9 million of a project sale. After adjustments for project sales, sales by the Analytics segment, which was sold in December 2009 and other one-time effects amounting EUR 8.1 million, sales in the comparable period of the previous year amounted to EUR 17.5 million, resulting in a Q3 2010 sales growth at product level of 14.3 percent to EUR 20.0 million. Comparing the figures for the previous third quarters, sales growth at product level was 20 percent from EUR 6.0 million (adjusted by one-time effects amounting EUR 4.9 million) to EUR 7.2 million.

aap is currently in negotiations on the distribution of various products such as the new Jason G® collagen fleece in Europe and of existing products, for instance the cannulated screws in the United States. We anticipate the signing of at least one contract in the course of the fourth quarter. These new contractual relations will be based both on existing partnerships and on partnerships with new customers, such as in the U.S., and will contribute to sales growth at product level partly in 2010 and fully in 2011. Negotiations in connection with our R&D partner programs have also reached an advanced stage.

As part of the ongoing focusing of our product portfolio we are also engaged in negotiations on the divestment of further non-core products. In the third quarter, aap achieved besides the product sales of EUR 0.9 million additional project sales due to the divestment of a non-core product in the Dental segment.

On the basis of current forecasts the Management Board assumes that the positive sales trend will continue in the fourth quarter of 2010 with the result that the double-digit sales growth target of around 15 percent at product level envisioned in the management agenda for 2010 can be achieved for the financial year.

aap plans to publish the Q3 2010 interim report in full on November 5, 2010.